Roche research executive reports on 3D liver assay

Roche (RHHBY -0.7%) Innovation Center Basel's Dr. Adrian Roth presented results from a collaborative study with Organovo (ONVO +9.1%) scientists using the company's 3D Human Liver Tissues at the 3D Cell Culture 2014 conference in Freiburg, Germany yesterday. The study, conducted at Organovo, showed that the 3D Liver Model was able to distinguish a hepatotoxic drug from a close non-toxic chemical analog. The model detected the toxicity at physiologically relevant doses.

Organovo plans to launch the 3D Human Liver Tissue in late Q4 2014 as a testing service performed at Organovo's laboratory. This is a change in strategy considering it originally stated that it would sell the "assay" or "model" on-line as a deliverable product. The name change and service-only offering implies that the product is not as fully-developed as planned.


From other sites
Comments (7)
  • zonaridge1123
    , contributor
    Comments (65) | Send Message
    How you spun this into negative is beyond me..WOW
    26 Jun 2014, 10:41 AM Reply Like
  • mackcap
    , contributor
    Comments (16) | Send Message
    I like their quality control concern by not shipping out and keeping clients in house.
    Keeps test results and their name intact.
    26 Jun 2014, 10:54 AM Reply Like
    , contributor
    Comments (14) | Send Message
    I have not seen any comments by Organovo that they will not sell the tissue or assay as they previously stated. The service they are offering is in addition to their previous plans. Many companies already contract these services out , just a smart move by onvo to offer the service and pick up additional income.
    26 Jun 2014, 11:28 AM Reply Like
  • tommyjoemac
    , contributor
    Comments (54) | Send Message
    I did look at the 8k form Organovo released and they said they are on schedule to sell assays by the end of the year. Now they are doing testing for customers in the Organovo labs, but see no problems with selling the assays as they previosly planned by the end of the year. If something else was released by the company please let me know.
    26 Jun 2014, 12:53 PM Reply Like
  • ECapo
    , contributor
    Comments (737) | Send Message
    Sounds as if they can make money by doing the testing in-house and expand sales also. Why can they not expand company and do both?
    26 Jun 2014, 01:44 PM Reply Like
  • regenmedprovider
    , contributor
    Comment (1) | Send Message
    I read that, "...implies..." statement from SA and just grinned. That's probably as good a shot across the bow as SA can take at this point, but still laughably obvious. Roche publicly reported physiologically relevant results yesterday. This is just the first of many positive KOL reports. The scientific community in this area (and the scientists) are a fairly tight community, they know each other, and each other's research quite well. Lots of cross-pollination and plenty of "pillow talk." Word is that ONVO's 3D tissue has "legs" and will be a game changer in the pharma field. It will provide toxicity and efficacy information much earlier in the process, reduce costs of bringing a new med to market, and reduce the risk of human trial errors at that point in the process. This is big news. With short interest running between 26-28%, Roche's report had to be an unpleasant surprise. Most shorts were predicting KOL results much much later.


    And the "implied" message of product progress lagging is ridiculous. Quite frankly, KUDO's to ONVO for keeping their product in house. To formalize that, I think, is genius! It solves several problems. 1. How do you maintain the integrity of the product in shipping and delivery. Heck, I can barely get stuff shipped intact to me from Amazon. The logistics of shipping live 3D tissue are massive and could definitely affect results. So kudo's to ONVO for adhering to quality product standards, which they can control, in their own facility. 2. I am sure that any "purchaser" will have their own scientists on board and domiciled for the duration of the testing, in the ONVO facility, a la what Roche has done and is obviously satisfied with. 3. If ONVO did "deliver" their proprietary 3D tissue to an off-site facility in the labs of various pharma companies, it runs the risk of those customers basically using the tissue, as well as the process and equipment to create/maintain it, as an opportunity to reverse-engineer the tissue and all build their own, thereby cutting out ONVO. I never saw the "delivery of tissue" as a good model.


    I'm just a lowly health care provider, listening to pharm reps and seeing patients every day with liver toxicity issues with meds, which ONVO tissue will help identify long before used in humans.
    26 Jun 2014, 03:56 PM Reply Like
  • lifestock
    , contributor
    Comments (29) | Send Message
    Couldn't agree more! This is amazing news!
    7 Jul 2014, 02:57 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs